Cargando…

Effects of olanzapine on resting heart rate in Japanese patients with schizophrenia

It has long been known that antipsychotic drugs (ATP) causes tachycardia, however details such as the differences between ATP are not well known. In recent years, the relationship between the rise in resting heart rate (RHR) and the increased risk of death in the general population has been garnerin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tajiri, Misuzu, Suzuki, Yutaro, Sugai, Takuro, Tsuneyama, Nobuto, Someya, Toshiyuki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6049914/ https://www.ncbi.nlm.nih.gov/pubmed/30016331 http://dx.doi.org/10.1371/journal.pone.0199922

Ejemplares similares

Effect of Serum Leptin on Weight Gain Induced by Olanzapine in Female Patients with Schizophrenia
por: Tsuneyama, Nobuto, et al.
Publicado: (2016)

Serum cortisol and insulin-like growth factor 1 levels in major depressive disorder and schizophrenia
por: Arinami, Hiroshi, et al.
Publicado: (2023)

Role of insulin-like growth factor 1, sex and corticosteroid hormones in male major depressive disorder
por: Arinami, Hiroshi, et al.
Publicado: (2021)

High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia: a nationwide survey
por: Sugai, Takuro, et al.
Publicado: (2015)

Psychiatrists' Attitudes toward Metabolic Adverse Events in Patients with Schizophrenia
por: Sugawara, Norio, et al.
Publicado: (2014)

High Prevalence of Obesity, Hypertension, Hyperlipidemia, and Diabetes Mellitus in Japanese Outpatients with Schizophrenia: A Nationwide Survey
por: Sugai, Takuro, et al.
Publicado: (2016)

Association Between the Number of Remaining Teeth and Body Mass Index in Japanese Inpatients with Schizophrenia
por: Otake, Masataka, et al.
Publicado: (2022)

High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey
por: Ono, Shin, et al.
Publicado: (2018)

Predictive Utility of Body Mass Index for Metabolic Syndrome Among Patients with Schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2020)

Attitudes toward metabolic adverse events among patients with schizophrenia in Japan
por: Sugawara, Norio, et al.
Publicado: (2016)

PS105. Effects of CYP2C19 genotype on steady-state plasma concentrations of escitalopram and desmetyl metabolite in Japanese depressed patients
por: Tsuchimine, Shoko, et al.
Publicado: (2016)

Effects of Cytochrome P450 (CYP) 2C19 Genotypes on Steady-State Plasma Concentrations of Escitalopram and its Desmethyl Metabolite in Japanese Patients With Depression
por: Tsuchimine, Shoko, et al.
Publicado: (2018)

The lowest effective plasma concentration of atomoxetine in pediatric patients with attention deficit/hyperactivity disorder: A non-randomized prospective interventional study
por: Sugimoto, Atsunori, et al.
Publicado: (2021)

Influence of Atomoxetine on Relationship Between ADHD Symptoms and Prefrontal Cortex Activity During Task Execution in Adult Patients
por: Sugimoto, Atsunori, et al.
Publicado: (2021)

Paroxetine combined with olanzapine in the treatment of schizophrenia
por: Wang, Ning, et al.
Publicado: (2020)

Treatment Continuation of Asenapine or Olanzapine in Japanese Schizophrenia Patients: A Propensity Score Matched Study
por: Matsuzaki, Haruna, et al.
Publicado: (2021)

Effect of Olanzapine on Clinical and Polysomnography Profiles in Patients with Schizophrenia
por: Katshu, Mohammad Zia Ul Haq, et al.
Publicado: (2018)

A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2013)

Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia
por: Katagiri, Hideaki, et al.
Publicado: (2018)

Worth the Weight? Olanzapine Prescribing in Schizophrenia. A Review of Weight Gain and Other Cardiometabolic Side Effects of Olanzapine
por: Fitzgerald, Ita, et al.
Publicado: (2021)

Effects of olanzapine on anhedonia in schizophrenia: mediated by complement factor H
por: Zhang, Yi, et al.
Publicado: (2023)

Application of Plasma Levels of Olanzapine and N-Desmethyl-Olanzapine to Monitor Clinical Efficacy in Patients with Schizophrenia
por: Lu, Mong-Liang, et al.
Publicado: (2016)

Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
por: An, Huimei, et al.
Publicado: (2022)

Direct metabolic effects of risperidone and olanzapine in Japanese schizophrenic patients
por: Nagamine, Takahiko
Publicado: (2007)

Erratum: A randomized, double-blind, placebo-controlled study of rapid-acting intramuscular olanzapine in Japanese patients for schizophrenia with acute agitation
por: Katagiri, Hideaki, et al.
Publicado: (2014)

Association analysis of the Cadherin13 gene with schizophrenia in the Japanese population
por: Otsuka, Ikuo, et al.
Publicado: (2015)

Altered Heart Rate Variability During Rest in Schizophrenia: A State Marker
por: Datta, Anjum, et al.
Publicado: (2023)

Depression, Anxiety and Primiparity are Negatively Associated with Mother–Infant Bonding in Japanese Mothers
por: Motegi, Takaharu, et al.
Publicado: (2020)

Effect of Co-Treatment of Olanzapine with SEP-363856 in Mice Models of Schizophrenia
por: Liang, Lingzhi, et al.
Publicado: (2022)

Effect of Haloperidol and Olanzapine on Hippocampal Cells’ Proliferation in Animal Model of Schizophrenia
por: Osacka, Jana, et al.
Publicado: (2022)

Comparison of Olanzapine versus Other Second-Generation Antipsychotics in the Improvement of Insight and Medication Discontinuation Rate in Schizophrenia
Publicado: (2018)

Effects of Olanzapine on Bone Mineral Density, Glucose, and Lipid Metabolism in Schizophrenia Patients
por: Liang, Mining, et al.
Publicado: (2019)

Effect of olanzapine combined with risperidone in the treatment of schizophrenia and its influence on cognitive function
por: Yang, Lujie, et al.
Publicado: (2021)

Change in level of productivity in the treatment of schizophrenia with olanzapine or other antipsychotics
por: Liu-Seifert, Hong, et al.
Publicado: (2011)

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
por: Shoja Shafti, Saeed, et al.
Publicado: (2014)

Subcutaneous Olanzapine at the End of Life in a Patient with Schizophrenia and Dysphagia
por: Hindmarsh, Jonathan, et al.
Publicado: (2020)

Prevalence of diabetes in patients of Schizophrenia on long-term use of olanzapine
Publicado: (2022)

Factor Structure and Measurement Invariance of the Hospital Anxiety and Depression Scale Across the Peripartum Period Among Pregnant Japanese Women
por: Ogawa, Maki, et al.
Publicado: (2021)

A naturalistic comparison of the efficacy and safety of intramuscular olanzapine and intramuscular levomepromazine in agitated elderly patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2013)

Combining samidorphan with olanzapine to mitigate weight gain as a side effect in schizophrenia treatment
por: Grywińska, Weronika B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_meo7i59ebnat9bu1ep9nsacboh